Pneumococcal vaccination in UK: an update. Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections

Size: px
Start display at page:

Download "Pneumococcal vaccination in UK: an update. Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections"

Transcription

1 Pneumococcal vaccination in UK: an update Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections

2 Leading infectious causes of mortality, 2000 WHO estimates 3.5 Deaths (millions) < 5 years old > 5 years old 1.7 S. pneumoniae: ~1.6 million deaths, including ~800,000 child deaths Pneumonia AIDS Diarrhoea TB Malaria Measles Source: WHO 2

3 Annual incidence per 100,000 of invasive pneumococcal infection E&W, by age group and year, Inability to to mount immune response to to capsule Waning immunity Non-immune factors mths 3-5 mths 6-11 mths mths mths mths mths 5-9 yrs yrs yrs yrs yrs yrs yrs yrs yrs yrs yrs yrs yrs yrs 75+ yrs

4 Burden of Pneumococcal disease Hospital Episode Statistics (HES) England Admission rate per 100,000 population/year Lobar pneumonia (HES-first diagnosis) Lobar pneumonia (HES-any diagnoses) IPD (HES-first diagnosis) IPD (HES-any diagnoses) IPD lab data) 0-4 Source: Melegaro et al Age group

5 Proportion of hospitalised pneumococcal cases reporting co-morbidity (1, 2-4 and 5+ diagnoses) Proportion of hospital admissions 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 5+ diagnoses 2-4 diagnoses 1 diagnosis <1 mths 1-11 mths Age group Source: Melegaro et al

6 Case-fatality ratio by age of IPD, pneumococcal pneumonia and lobar pneumonia Case-fatality ratio 45% 40% 35% 30% 25% 20% 15% 10% 5% Pnc meningitis and septicaemia Pnc pneumonia Lobar pneumonia Pnc confirmed 0% <1 mths 1-11 mths Source: Melegaro et al Age group 6

7 Burden of Pneumococcal disease GP consultation rate for CAP and OM 80,000 7,000 OM episode rate per 100,000 population/year 70,000 60,000 50,000 40,000 30,000 20,000 10,000 Otitis media (High risk) Otitis media (Non high risk) Pneumonia (High risk) Pneumonia (Non high risk) ` 6,000 5,000 4,000 3,000 2,000 1,000 Pneumonia episode rate per 100,000 population/year Source: Melegaro et al Age group

8 Pneumococcal polysaccharide vaccine Produced from purified capsular polysaccharide; Current vaccine contains 23 of the serotypes responsible for disease; Protects against invasive disease: BUT poor antibody responses in young children; do not induce immunologic memory, short term protection; hyporesponsiveness on revaccination do not protect against non-invasive diseases e.g. otitis media; do not reduce nasopharyngeal carriage.

9 Pneumococcal conjugate vaccines Pneumococcal conjugate vaccine contains 7 of the serotypes responsible for disease; Seek to prevent invasive and non-invasive (pneumonia and otitis media) disease. effective in young children; induce long-term memory; reduce Pnc carriage and induce herd immunity. 9

10 Coverage of vaccine serotypes in England and Wales by age: 7-valent conjugate and 23-valent polysacc vaccine Vaccine <5yrs 5-64 yrs 64+ yrs 7-valent (85.8) (51.2) (66.9) 23-valent Figures in ( ) based on assumption of full cross protection between serotypes within serogroups 10

11 Evolution of pneumococcal vaccination strategy in England and Wales Polysaccharide vaccine (23-valent) licensed in 1989: 1992 until 2003 recommended for risk groups >2 year olds post 2003 also recommended for elderly (>65 years) Conjugate vaccine (7-valent) licensed in 2001: post 2002 recommended for risk groups <2 years old post 2004 recommended for risk groups <5 years old post 2006 recommended for all infants

12 Risk groups for whom vaccine indicated asplenics (including sickle cell & coeliac disease); chronic lung disease; chronic heart disease; chronic renal disease; chronic liver disease (including cirrhosis); diabetes mellitus; immunocompromised (disease or treatment); HIV infection (at any stage); persons with cochlear implants. 12

13 Meta-analysis of polysaccharide vaccine efficacy for IPD (Melegaro et al ) Study [Fig. 2a] Odds ratio (95% CI) Study [Fig. 2b] Odds ratio (95% CI) Klastersky,RCT (1986) 0.80 (0.05,13.60) Honkanen,QRCT (1999) 0.37 (0.07,1.91) Simberkoff,RCT (1986) 2.01 (0.18,22.20) Gaillat,QRCT (1985) 0.27 (0.01,6.54) Leech,RCT (1987) 3.20 (0.13,79.47) Ortqvist,RCT (1998) 0.21 (0.02,1.77) Overall (95% CI) 0.35 (0.08,1.49) Overall (95% CI) 0.80 (0.22,2.88) 1 Odds ratio 1 Odds ratio Little or no evidence of efficacy against pneumonia (not shown) Limited evidence for efficacy against IPD in non-high risk individuals (lefthand panel & other studies) Little or no evidence of efficacy against IPD in high risk population (right hand panel)

14 Polysaccharide vaccine coverage in high-risk population and all elderly >65 years, General Practice Research Database, % 90% % Vaccinated 80% 70% 60% 50% 40% 30% 20% 10% 0% % high risk vacc % all vacc 14

15 New polysaccharide programme for the elderly, England and Wales from 20th August 2003: all people > aged 80 years from 1st April 2004: extended to all > aged 75 years from 1 st April 2005: extended to all > aged 65 years 15

16 Enhanced pneumococcal surveillance PPV coverage: 10 year historical coverage & previous 12 months uptake from GPs From August 2004 for 80+ From April 2005 for From April 2006 for Enhanced IPD surveillance: All serotyped IPD cases followed with GP to ascertain: - immunisation history; - outcome of infection; - underlying risk factors. 16

17 US pneumococcal conjugate vaccine efficacy trial: 2/4/6 months + 12 month booster PCV efficacy against Invasive disease vaccine serotypes (ST) 97.4% Invasive disease vaccine ST 1+ dose 85.7% Lobar pneumonia 73% Any pneumonia with abnormal CXR 33% Any otitis media episode 8.9% Recurrent OM 11.9% Ear tube placement 20.1% 17

18 Finnish Prevenar Efficacy Trial against Serotype-specific Culture-confirmed Acute Pneumococcal Otitis Media (AOM) in Infants and Children Episodes due to vaccine related serotypes 51% (27 to 97) Any culture confirmed pneumococcal AOM 34% (21 to 45%) AOM irrespective of aetiology 6% (-4 to 16%) Episodes due to non-vaccine serotypes - 33% (-80 to 1) Eskola J, et al NEJM 2001

19 19

20 Design of infant trial, UK PCV/PPV given concomitantly with DTaP 3 /Hib- TT + MCC- CRM 9V Conj at 2mths 9V Conj at 3 mths 9V Conj at 4 mths 23V Poly at 1yr 9V Conj at 1yr 20

21 7 6 5 Serotype-specific IgG GMCs after 3 doses (at 2/3/4 months) or 2 doses (at 2 and 4 months) of conjugate in UK infants compared with USA schedule* 3 dose 2 dose USA ug/ml B 9V 14 18C 19F 23F 1 5 pneumococcal serotype Source: Miller et al. *Data from Black et al PIDJ

22 Vaccination schedule in the UK 2006 Primary immunisation 2 months Diphtheria-tetanus-acellular pertussis, inactivated polio vaccine and Haemophilus influenzae type b Pneumococcal conjugate vaccine 3 months Diphtheria-tetanus-acellular pertussis, inactivated polio vaccine and Haemophilus influenzae type b Meningococcal group C conjugate 4 months Diphtheria-tetanus-acellular pertussis, inactivated polio vaccine and Haemophilus influenzae type b Meningococcal group C conjugate Pneumococcal conjugate vaccine DTaP-Hib-IPV PCV DTaP-Hib-IPV MenC DTaP-Hib-IPV MenC PCV 13 months Measles-mumps-rubella MMR 22

23 Vaccination schedule in the UK 2006 (continued) Booster immunisation 12 months Haemophilus influenzae type b Meningococcal group C conjugate Hib-MenC 13 months Pneumococcal conjugate vaccine PCV 3½-5 years Diphtheria-tetanus-acellular pertussis and inactivated polio vaccine DTaP-IPV or dtap/ipv Measles-mumps-rubella MMR years Tetanus-low dose diphtheria and inactivated polio vaccine Td-IPV 23

24 Cumulative Weekly Number of Reports of Invasive Pneumococcal Disease Due To One of the Serotypes Not Present in Prevenar for Children Aged 0-2 Years in England and Wales by Epidemiological Year: July - June (2003 to Date) 24

25 Cumulative Weekly Number of Reports of Invasive Pneumococcal Disease Due To One of the Seven Serotypes Present in Prevenar for Children Aged 0-2 Years in England and Wales by Epidemiological Year: July-June (2003 to Date) 25

26 Current issues Impact and effectiveness of current programme Pneumococcal clusters Emergence of non-7-valent PCV serotypes Pneumococcal vaccine development: 10-valent and 13-valent vaccines in advanced stages of testing At least one common protein candidate approaching large-scale clinical evaluation 26

27 Acknowledgments Prof. Liz Miller and the staff in the HPA Immunisation Dept especially Pauline Kaye, Usha Gungabissoon, and Nick Andrews; Dr Robert George, Dr Mary Slack and Siobhan Martin and all staff of the HPA Streptococcus and Diphtheria Reference Unit, RSIL; Dr Alessia Melegaro, John Edmunds and colleagues of the HPA Modelling and Economics Department; Prof. David Goldblatt of the Institute of Child Health, London Microbiologists, and General Practitioners across the country for referring IPD isolates, reporting infections and responding to all our (numerous) information requests. 27

Benefits of the pneumococcal immunisation programme in children in the United Kingdom

Benefits of the pneumococcal immunisation programme in children in the United Kingdom Benefits of the pneumococcal immunisation programme in children in the United Kingdom 2006-2014 Professor Mary P E Slack mpeslack@gmail.com March 2015 Disclosure of interest The presenter has received

More information

Experience with maternal pertussis and PCV13 immunisation in England

Experience with maternal pertussis and PCV13 immunisation in England Experience with maternal pertussis and PCV13 immunisation in England Immunisation, Hepatitis & Blood Safety department Public Health England 5th RIVM Vaccine Preventable Diseases Research day 18 th November

More information

Why is surveillance important after introducing vaccines?

Why is surveillance important after introducing vaccines? Why is surveillance important after introducing vaccines? Dr Michael Edelstein Immunisation Department, National Infections service Public Health England @epi_michael BSAC Spring conference, 12 th March

More information

SYNFLORIX TM. adsorbed on aluminium phosphate 0.5 milligram Al conjugated to protein D (derived from NTHi) carrier protein 9-16 micrograms 3

SYNFLORIX TM. adsorbed on aluminium phosphate 0.5 milligram Al conjugated to protein D (derived from NTHi) carrier protein 9-16 micrograms 3 1. NAME OF THE MEDICINAL PRODUCT SYNFLORIX TM Synflorix TM suspension for injection Pneumococcal polysaccharide conjugate vaccine (adsorbed) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 ml)

More information

Impact of vaccination on epidemiology in adults

Impact of vaccination on epidemiology in adults Impact of vaccination on epidemiology in adults Jan Verhaegen 1. Data on prospective study on IPD in Belgium (2009-2011) 2. Evolution of capsular types of invasive isolates from adults after introduction

More information

Public Health Wales Vaccine Preventable Disease Programme

Public Health Wales Vaccine Preventable Disease Programme Public Health Wales Vaccine Preventable Disease Programme LHB practice level reports Cwm Taf LHB July June August Page of Contents. Purpose and Background.... LHB Summary.... Practice level data Merthyr

More information

BCG vaccine and tuberculosis

BCG vaccine and tuberculosis PART 2: Vaccination for special risk groups 2.1 Vaccination for Aboriginal and Torres Strait Islander people Aboriginal and Torres Strait Islander people historically had a very high burden of infectious

More information

Immunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012

Immunization Update: New CDC Recommendations. Blaise L. Congeni M.D. 2012 Immunization Update: New CDC Recommendations Blaise L. Congeni M.D. 2012 Polysaccharide Vaccines Vaccine Hib capsule polysaccharide PRP (polyribose ribitol phosphate) Not protective in infants

More information

Pneumococcal polysaccharide vaccine uptake in England, , prior to the introduction of a vaccination programme for older adults

Pneumococcal polysaccharide vaccine uptake in England, , prior to the introduction of a vaccination programme for older adults Journal of Public Health Advance Access published July 7, 2006 Journal of Public Health pp. 1 of 6 doi:10.1093/pubmed/fdl017 Pneumococcal polysaccharide vaccine uptake in England, 1989 2003, prior to the

More information

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office.

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office. The National Immunisation Schedule Update and Current issues Dr Brenda Corcoran National Immunisation Office : Dates vaccines introduced into the Irish immunisation schedule Vaccine 1937-1999 Date introduced

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) 2. QUALITATIVE AND

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Synflorix suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (adsorbed) 2. QUALITATIVE

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Synflorix suspension for injection in pre-filled syringe Synflorix suspension for injection Synflorix suspension for injection

More information

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory SYNFLORIX

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory SYNFLORIX For the use only of Registered Medical Practitioners or a Hospital or a Laboratory SYNFLORIX Pneumococcal Polysaccharide Conjugate Vaccine (adsorbed) Ph. Eur. 1. NAME OF THE MEDICINAL PRODUCT Pneumococcal

More information

What DO the childhood immunization footnotes reveal? Questions and answers

What DO the childhood immunization footnotes reveal? Questions and answers What DO the childhood immunization footnotes reveal? Questions and answers Stanley E. Grogg, DO, FACOP, FAAP he Advisory Committee on Immunization Practices (ACIP) recommends the childhood vaccination

More information

Pneumococcal Disease and Pneumococcal Vaccines

Pneumococcal Disease and Pneumococcal Vaccines Pneumococcal Disease and Epidemiology and Prevention of - Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition website at

More information

Synflorix. Pneumococcal polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine, adsorbed

Synflorix. Pneumococcal polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine, adsorbed Synflorix Pneumococcal polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine, adsorbed QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5 ml) contains 1 microgram

More information

Healthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.

Healthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020. Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) 2. QUALITATIVE AND

More information

2016/17 Vaccination and Immunisation list of additional services and enhanced services

2016/17 Vaccination and Immunisation list of additional services and enhanced services 2016/17 Vaccination and Immunisation list of additional services and enhanced services 2016/17 Vaccination and Immunisation list of additional services and enhanced services Version number: 1 First published:

More information

Syrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation

Syrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation Syrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation Background Information Immunisation services in Syria Syria had good immunisation services,

More information

2017/18 Immunisation programmes list of additional and enhanced services

2017/18 Immunisation programmes list of additional and enhanced services 2017/18 Immunisation programmes list of additional and enhanced services 2017/18 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2017 Prepared

More information

Pneumococcal vaccines. Safety & Efficacy. Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh

Pneumococcal vaccines. Safety & Efficacy. Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh Pneumococcal vaccines Safety & Efficacy Prof. Rajesh Kumar, MD PGIMER School of Public Health Chandigarh Disclosure Slide X X I DO NOT have any significant or other financial relationships with industry

More information

2018/19 Immunisation programmes list of additional and enhanced services

2018/19 Immunisation programmes list of additional and enhanced services 2018/19 Immunisation programmes list of additional and enhanced services 2018/19 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2018 Prepared

More information

Haemophilus influenzae

Haemophilus influenzae Haemophilus influenzae type b Severe bacterial infection, particularly among infants During late 19th century believed to cause influenza Immunology and microbiology clarified in 1930s Haemophilus influenzae

More information

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office.

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office. The National Immunisation Schedule Update and Current issues Dr Brenda Corcoran National Immunisation Office Objectives To outline immunisation schedules in Ireland Primary childhood schedule Vaccine uptake

More information

NOTE: The above recommendations must be read along with the footnotes of this schedule.

NOTE: The above recommendations must be read along with the footnotes of this schedule. Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read

More information

Streptococcus pneumoniae CDC

Streptococcus pneumoniae CDC Streptococcus pneumoniae CDC Pneumococcal Disease Infection caused by the bacteria, Streptococcus pneumoniae» otitis media 20 million office visits (28-55% Strep)» pneumonia 175,000 cases annually» meningitis

More information

Communicable Disease & Immunization

Communicable Disease & Immunization Communicable Disease & Immunization Ingham County Health Surveillance Book 2016 Communicable Disease & Immunization - 1 Communicable Disease & Immunization T he control of communicable disease and immunization,

More information

Synflorix. Pneumococcal polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine, adsorbed

Synflorix. Pneumococcal polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine, adsorbed Synflorix Pneumococcal polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine, adsorbed QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5 ml) contains 1 microgram

More information

Cyprus Experience. Dr. Elena Papamichael Ministry of Health

Cyprus Experience. Dr. Elena Papamichael Ministry of Health Cyprus Experience Dr. Elena Papamichael Ministry of Health Cyprus became independent on1960. On 1974, Turkish troops invaded in the island disturbing the willing for peaceful living. Since then, Turkey

More information

Appendix An Assessment Tool to Determine the Validity of Vaccine Doses

Appendix An Assessment Tool to Determine the Validity of Vaccine Doses Appendix 4.4 - An Assessment Tool to Determine the Validity of Vaccine Doses Note: Refer to the Canadian Immunization Guide and New Brunswick (NB) immunization program directives for recommendations for

More information

Pneumococcal vaccines

Pneumococcal vaccines Pneumococcal vaccines Marco Aurélio Sáfadi, MD, PhD FCM da Santa Casa de São Paulo Challenges in establishing the baseline burden of disease, before implementing a vaccination program S. pneumoniae disease

More information

immunisation in New Zealand

immunisation in New Zealand This appendix details the history of. Section A1.1 is a brief summary of when each vaccine was introduced to the National Immunisation Schedule (the Schedule). This summary includes vaccines which were

More information

3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups

3 rd dose. 3 rd or 4 th dose, see footnote 5. see footnote 13. for certain high-risk groups Figure 1. Recommended immunization schedule for persons aged 0 through 18 years 2013. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations must be read

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Prevenar suspension for injection Pneumococcal saccharide conjugated vaccine, adsorbed 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

More information

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory SYNFLORIX

For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory SYNFLORIX For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory SYNFLORIX Pneumococcal Polysaccharide and Non-Typeable Haemophilus influenzae (NTHi) Protein D Conjugate Vaccine, adsorbed

More information

Requirements for new trials to examine offtarget. vaccination. Workshop on: Off-target (heterologous/non-specific) effects of vaccination.

Requirements for new trials to examine offtarget. vaccination. Workshop on: Off-target (heterologous/non-specific) effects of vaccination. Requirements for new trials to examine offtarget effects of vaccination Workshop on: Off-target (heterologous/non-specific) effects of vaccination Les Pensieres Jun 8-10, 2015 PEM Fine London School of

More information

Vaccinations for Adults

Vaccinations for Adults Case: Vaccinations for Adults Lisa Winston, MD University of California, San Francisco San Francisco General Hospital A 30-year old healthy woman comes for a routine visit. She is recently married and

More information

2016 Academic Review for the New Zealand National Immunisation Schedule: Pneumococcal ten valent vaccine effectiveness and safety

2016 Academic Review for the New Zealand National Immunisation Schedule: Pneumococcal ten valent vaccine effectiveness and safety 2016 Academic Review for the New Zealand National Immunisation Schedule: Pneumococcal ten valent vaccine effectiveness and safety Prepared as part of a Ministry of Health contract for services by the Immunisation

More information

The schedule for childhood vaccination is:(web link to NHS Childhood Immunisation Schedule for 2008

The schedule for childhood vaccination is:(web link to NHS Childhood Immunisation Schedule for 2008 Immunisations and vaccinations Immunisation is an effective public health intervention for promoting good health and protecting individuals and populations against serious disease and infection through

More information

ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults

ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults National Center for Immunization & Respiratory Diseases Respiratory Diseases Branch ACIP

More information

Surveillance of invasive pneumococcal infection in Belgium

Surveillance of invasive pneumococcal infection in Belgium Surveillance of invasive pneumococcal infection in Belgium National Reference Laboratory Start in 198 Laboratory Microbiology UH Leuven (prof. J. Vandepitte) Capsular type determination Antibiotic susceptibility

More information

2016 Vaccine Preventable Disease Summary

2016 Vaccine Preventable Disease Summary 2016 Vaccine Preventable Disease Summary 12251 James Street Holland, MI 49424 www.miottawa.org/healthdata Prepared October 2017 2016 Summary of Vaccine Preventable Diseases (VPDs) Reported to Ottawa County

More information

Bacterial diseases caused by Streptoccus pneumoniae in children

Bacterial diseases caused by Streptoccus pneumoniae in children Bacterial diseases caused by Streptoccus pneumoniae in children Bactermia 85% Bacterial pneumonia 66% Bacterial meningitis 50% Otitis media 40% Paranasal sinusitis 40% 0% 10% 20% 30% 40% 50% 60% 70% 80%

More information

Adolescent vaccination strategies

Adolescent vaccination strategies Adolescent vaccination strategies Gregory Hussey Vaccines for Africa Initiative Institute of Infectious Diseases & Molecular Medicine University of Cape Town www.vacfa.uct.ac.za gregory.hussey@uct.ac.za

More information

for the New Zealand National Immunisation Schedule: Pneumococcal Auckland UniServices Limited A wholly owned company of The University of Auckland

for the New Zealand National Immunisation Schedule: Pneumococcal Auckland UniServices Limited A wholly owned company of The University of Auckland 2012 Antigen Review for the New Zealand National Immunisation Schedule: Pneumococcal Auckland UniServices Limited A wholly owned company of The University of Auckland Prepared for: New Zealand Ministry

More information

Pneumococcal Vaccine Effectiveness. Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA

Pneumococcal Vaccine Effectiveness. Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA Pneumococcal Vaccine Effectiveness Steven Black, MD Center for Global Health Cincinnati Children s s Hospital Cincinnati, Ohio USA Overview Possible effectiveness outcomes for pneumococcal vaccines Pre-licensure

More information

I mun u i n s i atio i n o n u p u d p a d te

I mun u i n s i atio i n o n u p u d p a d te Immunisation update Brian Eley Paediatric Infectious Diseases Unit Red Cross War Memorial Children s Hospital Department of Paediatrics and Child Health University of Cape Town Immunisation schedules,

More information

Polysaccharide and conjugate vaccine responses

Polysaccharide and conjugate vaccine responses Hyporesponsiveness Kim Mulholland Murdoch Childrens Research Institute, Melbourne London School of Hygiene and Tropical Medicine, UK University of Melbourne, Australia Hyporesponsiveness Reduced or absent

More information

- Infanrix hexa (DTPa-HBV-IPV/Hib): GSK Biologicals combined diphtheria, tetanus, acellular pertussis, hepatitis

- Infanrix hexa (DTPa-HBV-IPV/Hib): GSK Biologicals combined diphtheria, tetanus, acellular pertussis, hepatitis The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

X THIS SUMMARY DOES NOT INCLUDE ! THIS SUMMARY INCLUDES

X THIS SUMMARY DOES NOT INCLUDE ! THIS SUMMARY INCLUDES OPTIMIZING PNEUMOCOCCAL CONJUGATE VACCINES (PCV) SCHEDULES FOR CHILDREN IN VARIOUS AREAS OF THE WORLD What is the relative effect of administering PCV vaccines using a 3 primary doses (3p) versus 2 primary

More information

Acknowledgements. Introduction. Structure of the video

Acknowledgements. Introduction. Structure of the video Educators Guide Acknowledgements The Ministry of Health would like to thank Blue Bicycle Flicks. Thanks also to the staff and students from Evans Bay Intermediate School who contributed to the shooting

More information

OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE

OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE Dr Tiong Wei Wei, MD, MPH Senior Assistant Director Policy and Control Branch, Communicable Diseases Division Ministry of Health 9

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Synflorix suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (adsorbed) 2. QUALITATIVE

More information

Economic aspects of viral hepatitis in Turkey. Levent AKIN VIRAL HEPATITIS PREVENTION BOARD MEETING ISTANBUL, TURKEY, NOVEMBER 12-13, 2009

Economic aspects of viral hepatitis in Turkey. Levent AKIN VIRAL HEPATITIS PREVENTION BOARD MEETING ISTANBUL, TURKEY, NOVEMBER 12-13, 2009 Economic aspects of viral hepatitis in Turkey Levent AKIN VIRAL HEPATITIS PREVENTION BOARD MEETING ISTANBUL, TURKEY, NOVEMBER 12-13, 2009 Vaccines currently recommended for children in National Immunization

More information

National Immunisation Programme changes Michael Baker. Wessex Public Health England Centre

National Immunisation Programme changes Michael Baker. Wessex Public Health England Centre National Immunisation Programme changes 2013-14 Michael Baker Wessex Public Health England Centre Changes to the Meningococcal serogroup C conjugate (MenC) vaccine schedule in 2013 2 Immunisation Programme

More information

History and aims of immunisation. Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8

History and aims of immunisation. Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8 History and aims of immunisation Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8 Objectives To examine the history of immunisation To explain the aim of immunisation To develop

More information

These slides are the property of the presenter. Do not duplicate without express written consent.

These slides are the property of the presenter. Do not duplicate without express written consent. Cancer Survivorship Protecting Against Vaccine Preventable Diseases Heidi Loynes BSN, RN Immunization Nurse Educator Michigan Department of health and Human Services (MDHHS) loynesh@michigan.gov Are Vaccine-Preventable

More information

Pneumococcal Vaccine Introductions Dr. Carsten Mantel WHO/FCH/IVB/EPI

Pneumococcal Vaccine Introductions Dr. Carsten Mantel WHO/FCH/IVB/EPI Pneumococcal Vaccine Introductions 2012 Dr. Carsten Mantel WHO/FCH/IVB/EPI Pneumonia is leading cause of death in children < 5 yrs * Pneumococcus and Hib are the two leading causes of life-threatening

More information

Pediatric and Adolescent Vaccines

Pediatric and Adolescent Vaccines Pediatric and Adolescent Vaccines Andrea A. Berry, M.D. Division of Infectious Diseases and Tropical Pediatrics Center for Vaccine Development & Division of Malaria Research Overview Pediatric vaccine

More information

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET NEW ZEALAND DATA SHEET 1. PRODUCT NAME SYNFLORIX pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed. Suspension for injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (0.5 ml)

More information

What are the new active vaccine recommendations in the Canadian Immunization Guide?

What are the new active vaccine recommendations in the Canadian Immunization Guide? 154 CCDR 17 April 2014 Volume 40-8 https://doi.org/10.14745/ccdr.v40i08a03 1 What are the new active vaccine recommendations in the Canadian Immunization Guide? Warshawsky B 1 and Gemmill I 2 on behalf

More information

Report of Typing & Antimicrobial Susceptibilities of Isolates Causing Invasive Pneumococcal Disease in Ireland,

Report of Typing & Antimicrobial Susceptibilities of Isolates Causing Invasive Pneumococcal Disease in Ireland, Report of Typing & Antimicrobial Susceptibilities of Isolates Causing Invasive Pneumococcal Disease in Ireland, 2011-2013 1. Background Streptococcus pneumoniae is a major cause of life-threatening infections

More information

Hyporesponsiveness: Time To Stop Using Meningococcal Polysaccharide Vaccines?

Hyporesponsiveness: Time To Stop Using Meningococcal Polysaccharide Vaccines? Hyporesponsiveness: Time To Stop Using Meningococcal Polysaccharide Vaccines? Lee H. Harrison, M.D. Professor of Medicine and Epidemiology University of Pittsburgh First Regional Meningococcal Symposium

More information

Changes to the National Immunisation Schedule

Changes to the National Immunisation Schedule 17 December 2013 Changes to the National Immunisation Schedule PHARMAC is pleased to announce decisions related to the National Immunisation Schedule (NIS) that will take effect from 1 July 2014. This

More information

Prevention of pneumococcal disease in Canadian adults Old and New. Allison McGeer, MSc, MD, FRCPC Mount Sinai Hospital University of Toronto

Prevention of pneumococcal disease in Canadian adults Old and New. Allison McGeer, MSc, MD, FRCPC Mount Sinai Hospital University of Toronto Prevention of pneumococcal disease in Canadian adults Old and New Allison McGeer, MSc, MD, FRCPC Mount Sinai Hospital University of Toronto Objectives Review epidemiology of pneumococcal disease in adults

More information

Manitoba Health, Healthy Living and Seniors

Manitoba Health, Healthy Living and Seniors Manitoba Health, Healthy Living and Seniors Manitoba Annual Immunization Surveillance Report, 2012 and 2013 January 1, 2012 to December 31, 2013 with 5-year average comparison (January 1, 2007 to December

More information

Importer / Manufacturer: Wyeth (Thailand) Ltd./ Wyeth Pharmaceutical Division of Wyeth Holdings Corporation, Pearl River, NY 10965, USA

Importer / Manufacturer: Wyeth (Thailand) Ltd./ Wyeth Pharmaceutical Division of Wyeth Holdings Corporation, Pearl River, NY 10965, USA Registration No. 1C 13/46 (N) Importer / Manufacturer: Wyeth (Thailand) Ltd./ Wyeth Pharmaceutical Division of Wyeth Holdings Corporation, Pearl River, NY 10965, USA SUMMARY OF PRODUCT CHARACTERISTICS

More information

Manitoba Annual Immunization Surveillance Report

Manitoba Annual Immunization Surveillance Report Annual Immunization Surveillance Report January 1 to December 31, 2014 Epidemiology & Surveillance Public Branch Public and Primary Care Division, y Living and Seniors Released: January 2016 TABLE OF CONTENTS

More information

Annual Immunisation and Vaccine Preventable Diseases Report for Northern Ireland

Annual Immunisation and Vaccine Preventable Diseases Report for Northern Ireland Annual Immunisation and Vaccine Preventable Diseases Report for Northern Ireland 2016-17 Acknowledgements The Public Health Agency immunisation team would like to thank everyone who works so hard across

More information

Changes to the Meningococcal C conjugate (MenC) vaccine schedule. Questions and Answers

Changes to the Meningococcal C conjugate (MenC) vaccine schedule. Questions and Answers Changes to the Meningococcal C conjugate (MenC) vaccine schedule Questions and Answers Background The meningococcal C (MenC) vaccination programme was first introduced into the UK routine immunisation

More information

Downloaded from:

Downloaded from: Granerod, J; Davison, KL; Ramsay, ME; Crowcroft, NS (26) Investigating the aetiology of and evaluating the impact of the Men C vaccination programme on probable meningococcal disease in England and Wales.

More information

New Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines

New Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines New Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines Antigens Vaccine Approved Age Daptacel Diphtheria, Tetanus, and acellular Pertussis (DTaP)

More information

Full public health impact or. cherry-picking?

Full public health impact or. cherry-picking? Full public health impact or cherry-picking? Arto Palmu, MD, PhD, Research manager, head of Clinical Research Team, Department of Public Health Solutions 10.11.2017 Arto Palmu / RIVM2017 1 Disclosure The

More information

Update on Vaccine Recommendations. Objectives. Childhood Immunization Schedule At the Turn of the Century. New Horizons in Pediatrics April 30, 2017

Update on Vaccine Recommendations. Objectives. Childhood Immunization Schedule At the Turn of the Century. New Horizons in Pediatrics April 30, 2017 Centers for for Disease Disease Control Control and and Prevention Prevention National Center for Immunization and Respiratory Diseases Update on Vaccine Recommendations New Horizons in Pediatrics April

More information

Utah s Immunization Rule Individual Vaccine Requirements

Utah s Immunization Rule Individual Vaccine Requirements Utah s Immunization Rule Individual Vaccine Requirements Which vaccines are required for school entry in Utah? Grades K-6: 5 doses DTaP (4 doses if the 4 th dose was given after the 4 th birthday) 4 doses

More information

Pfizer Laboratories (Pty) Ltd PREVENAR 13 Suspension for Injection Final Approved Package Insert 26 November 2015 Page 1 of 16

Pfizer Laboratories (Pty) Ltd PREVENAR 13 Suspension for Injection Final Approved Package Insert 26 November 2015 Page 1 of 16 Page 1 of 16 SCHEDULING STATUS: S2 PROPRIETARY NAME (and dosage form): PREVENAR 13 (Ready-to-use Suspension for Injection) COMPOSITION: PREVENAR 13 is a sterile solution of saccharides of the capsular

More information

CHILDHOOD VACCINATION

CHILDHOOD VACCINATION EPI (3) Age of Child How and Where is it given? CHILDHOOD VACCINATION Nicolette du Plessis Block 10 28/02/2012 10 weeks DTaP-IPV/Hib (2) Diphtheria, Tetanus, Acellular pertussis, Inactivated polio vaccine,

More information

Recommended Health Screenings

Recommended Health Screenings Recommended Health Screenings UnitedHealthcare appreciates the preventive care you deliver to our members. Please use the below health screening chart to schedule screenings based on the member s age and

More information

Summary of Methods. Figure 1: Vaccines have been very effective in reducing most vaccine-preventable diseases in Colorado.

Summary of Methods. Figure 1: Vaccines have been very effective in reducing most vaccine-preventable diseases in Colorado. The Children s Hospital March 2004 Marsha Anderson, MD James Todd, MD Vaccine-preventable Diseases in Colorado s Children, 2002 For More Information: The Children s Hospital Public Affairs Department 303-861-8555

More information

Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) Ph.Eur., 13-valent PREVENAR 13

Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) Ph.Eur., 13-valent PREVENAR 13 For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) Ph.Eur., 13-valent PREVENAR 13 1. NAME OF THE MEDICINAL PRODUCT

More information

Vaccines and other immunological antimicrobial therapy 1

Vaccines and other immunological antimicrobial therapy 1 Vaccines and other immunological antimicrobial therapy 1 Vaccines Vaccine: a biological preparation that provides active acquired immunity to a particular disease. Vaccine typically contains an agent that

More information

We have a new vaccine: Now what are we going to do with it? Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci

We have a new vaccine: Now what are we going to do with it? Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci We have a new vaccine: Now what are we going to do with it? Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci Pressures for new vaccine introduction. International institutions. Vaccine manufacturers National

More information

RECOMMENDED IMMUNIZATIONS

RECOMMENDED IMMUNIZATIONS Recommended Immunization Schedule for Persons Aged 0 Through 6 Years United States 2010 1 2 4 6 12 15 18 19 23 2 3 4 6 Vaccine Age Birth month months months months months months months months years years

More information

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office.

The National Immunisation Schedule Update and Current issues. Dr Brenda Corcoran National Immunisation Office. The National Immunisation Schedule Update and Current issues Dr Brenda Corcoran National Immunisation Office Objectives To outline immunisation schedules in Ireland Primary childhood schedule Vaccine uptake

More information

7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids

7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids 7.0 Nunavut Childhood and Adult Immunization Schedules and Catch-up Aids Contents Introduction Nunavut Recommended Childhood Immunization Schedule Nunavut Routine Adult Immunization Schedule Nunavut Immunization

More information

Recommended Childhood Immunization Schedu...ates, January - December 2000, NP Central

Recommended Childhood Immunization Schedu...ates, January - December 2000, NP Central Recommended Childhood Immunization Schedule United States, January - December 2000 Vaccines 1 are listed under routinely recommended ages. Solid-colored bars indicate range of recommended ages for immunization.

More information

Efficacy of Pneumococcal Conjugate Vaccines (PCV) against Otitis Media

Efficacy of Pneumococcal Conjugate Vaccines (PCV) against Otitis Media Efficacy of Pneumococcal Conjugate Vaccines (PCV) against Otitis Media Terhi Kilpi National Public Health Institute Department of Vaccines 3rd Regional Pneumococcal Symposium 13 Feb 2008 Incidence of AOM

More information

Adult Pneumococcal Disease

Adult Pneumococcal Disease Adult Pneumococcal Disease Reviewed and updated July 2018 S. pneumoniae and pneumococcal disease The bacterium Streptococcus pneumoniae causes pneumococcal disease S. pneumoniae is commonly found in human

More information

Two-in-one: GSK s candidate PHiD-CV dual pathogen vaccine

Two-in-one: GSK s candidate PHiD-CV dual pathogen vaccine Two-in-one: GSK s candidate PHiD-CV dual pathogen vaccine Dr. Bernard Hoet Director, Medical affairs GlaxoSmithKline Biologicals Rixensart, Belgium Istanbul, Feb 13, 2008 PHiD-CV: A novel concept in Bacterial

More information

Guidelines for the immunisation of children following treatment with Standard-Dose Chemotherapy

Guidelines for the immunisation of children following treatment with Standard-Dose Chemotherapy Guidelines for the immunisation of children following treatment with Standard-Dose Chemotherapy Version 2.0 Approved by Haem / Onc Senior Clinical Management team Date Approved March 2015 Ratified by:

More information

Immunisation Update for Occupational Health

Immunisation Update for Occupational Health Immunisation Update for Occupational Health Dr Gayatri Amirthalingam Immunisation, Hepatitis & Blood Safety department Public Health England 29 th April 2016 Session Outline Epidemiology of vaccine preventable

More information

Immunisation Subcommittee of PTAC Meeting held 10 February (minutes for web publishing)

Immunisation Subcommittee of PTAC Meeting held 10 February (minutes for web publishing) Immunisation Subcommittee of PTAC Meeting held 10 February 2014 (minutes for web publishing) Immunisation Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

More information

Chapter 16 Pneumococcal Infection. Pneumococcal Infection. August 2015

Chapter 16 Pneumococcal Infection. Pneumococcal Infection. August 2015 Chapter 16 16 PPV introduced for at risk 1996 PCV7 introduced for at risk 2002 and as routine 2008 PCV13 replaced PCV7 in 2010 NOTIFIABLE In some circumstances, advice in these guidelines may differ from

More information

NOTE: The above recommendations must be read along with the footnotes of this schedule.

NOTE: The above recommendations must be read along with the footnotes of this schedule. Figure 1. Recommended immunization schedule for persons aged 0 through 18 years United States, 2014. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). These recommendations

More information

1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast ( ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector

1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast ( ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector 1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast (2006 ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector wise) (2005 ) 4. Worldwide Pediatric Vaccines Market Share

More information

2015 Vaccine Preventable Disease Summary

2015 Vaccine Preventable Disease Summary 2015 Vaccine Preventable Disease Summary 12251 James Street Holland, MI 49424 www.miottawa.org/healthdata Prepared April 2016 2015 Summary of Vaccine Preventable Diseases (VPD) Reported to Ottawa County

More information

S. Michael Marcy Memorial Lecture

S. Michael Marcy Memorial Lecture S. Michael Marcy Memorial Lecture Lessons Learned from Making Vaccine Recommendations Larry K. Pickering, MD, FAAP April 16, 2016 Los Angeles, CA FINANCIAL DISCLOSURE: Larry K. Pickering, M.D., F.A.A.P.

More information

Potential Impact of Conjugate Vaccine on the Incidence of Invasive Pneumococcal Disease among Children in Scotland

Potential Impact of Conjugate Vaccine on the Incidence of Invasive Pneumococcal Disease among Children in Scotland JOURNAL OF CLINICAL MICROBIOLOGY, Apr. 2006, p. 1224 1228 Vol. 44, No. 4 0095-1137/06/$08.00 0 doi:10.1128/jcm.44.4.1224 1228.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved.

More information